12 July 2024NewsBig PharmaMarisa Woutersen

Novo Nordisk’s uphill battle in the counterfeit weight loss craze

As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Eli Lilly takes further action over ‘dangerous’ diabetes drug fakes

25 June 2024 US drugmaker files six lawsuits over compounded tirzepatide products | At least five deaths associated with ‘generic’ Mounjaro, according to complaint | Fears over drug's 'unapproved' use for cosmetic weight loss.

Big Pharma

Ozempic counterfeits prompt Novo Nordisk to join forces with authorities

12 March 2024 Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Novo Nordisk’s uphill battle in the counterfeit weight loss craze

More on this story

Editor's picks

Editor's picks

More features